Localized in vivo prodrug activation using radionuclides.

A preprint abstract from biorxiv.org discusses a strategy called "RAdionuclide induced Drug Engagement for Release" (RAiDER) that aims to deliver combined radiation and chemotherapy to tumor sites while minimizing exposure to off-target sites. The study tested the effectiveness of different radionuclides in chemically activating a model radiation-activated prodrug. Results showed that RAiDER with certain radionuclides increased the cytotoxicity of the prodrug and delayed tumor growth in mouse models of cancer. The study suggests that RAiDER has the potential to improve the efficacy of radiopharmaceutical therapies for cancer treatment. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]